Mesoblast Limited vs Northrop Grumman Corporation — how do they compare? Mesoblast Limited trades at $16.38 (market cap $2.17B), while Northrop Grumman Corporation trades at $512 (market cap $74.42B). The key difference: Northrop Grumman Corporation is far larger — about 34.3× Mesoblast Limited's market cap, and Northrop Grumman Corporation pays a 1.79% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | NOC | |
|---|---|---|
Market Cap | $2.17B | $74.42B |
Sector | Technology | Industrials |
52-Week High | $20.96 | $768.02 |
52-Week Low | $12.88 | $496.02 |
Enterprise Value | $2.17B | $88.65B |
Dividend Yield | — | 1.79% |
Trailing returns across standard periods
Latest headlines on both assets
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →